Chemoimmunotherapy Followed by Surgery and Possible Radiation for Limited Spread Esophageal and Gastric Cancer TORO Protocol

What this Trial Is About

Esophageal cancer and cancers of the gastroesophageal junction GEJ are common and serious worldwide, especially when they have spread. Patients with a limited number of metastases, called oligometastatic disease, often have a better outlook than those with widespread cancer. This trial aims to evaluate the effects of combining pre-operative chemoimmunotherapy with surgery and possibly targeted radiation SBRT in treating oligometastatic esophageal and gastric cancers to better understand survival and recurrence outcomes. Participants will receive pre-operative chemoimmunotherapy followed by surgery to remove cancerous tissue. In some cases, targeted radiation SBRT may also be given to treat remaining metastases. This approach is being studied to see if adding surgery and radiation to chemoimmunotherapy improves outcomes. The study is a phase II clinical trial and will assess the safety and effectiveness of this combined treatment approach. Throughout the study, participants will have regular assessments including survival tracking for up to five years. Safety will be monitored closely, especially during the first 30 days after surgery, along with progression-free survival measured at two and five years. Quality of life questionnaires will be completed at several time points before and after treatment to understand the impact on daily living. This comprehensive monitoring aims to provide a clearer picture of how this treatment affects both cancer control and patient well-being.

Chemoimmunotherapy Followed by Surgery for Oligometastatic Esophagogastric Cancer: (TORO Protocol)